SCHEMBL27309535

SCHEMBL27309535

CCc1nc(N)cc(Cl)c1C(F)(F)F

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRB3 P28472 7/20 0.36
GABRA2 P47869 4/20 0.36
GABRB2 P47870 4/20 0.36
HEXA P06865 2/20 0.35
HEXB P07686 2/20 0.35
NOS3 P29474 1/20 0.34
NOS2 P35228 1/20 0.34
JUN P05412 1/20 0.34
NFKB1 P19838 1/20 0.34
NFKB2 Q00653 1/20 0.34
RELA Q04206 1/20 0.34
GABRP O00591 1/20 0.33
GABRD O14764 1/20 0.33
GABRA1 P14867 1/20 0.33
GABRB1 P18505 1/20 0.33
GABRG2 P18507 1/20 0.33
GABRA5 P31644 1/20 0.33
GABRA3 P34903 1/20 0.33
GABRA4 P48169 1/20 0.33
GABRE P78334 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22062839 0.81 REN (0.41) GABRB3GABRA2GABRB2HEXAHEXB
SCHEMBL22062889 0.81 GABRP (0.38) GABRB3GABRA2GABRB2HEXAHEXB
SCHEMBL24615642 0.77 HSP90AA1 (0.36) GABRB3GABRA2GABRB2NOS3NOS2
SCHEMBL31234990 0.77 HSP90AA1 (0.36) GABRB3GABRA2GABRB2NOS3NOS2
SCHEMBL24331214 0.76 BACE1 (0.34) NOS3NOS2ALDH1A1SMN1; SMN2
SCHEMBL22029121 0.72 KRAS (0.37) GABRB3GABRA2GABRB2NOS3NOS2
SCHEMBL30826909 0.72 KRAS (0.37) GABRB3GABRA2GABRB2NOS3NOS2
SCHEMBL27300605 0.72 NOS2 (0.34) NOS3NOS2CYP3A4CYP2D6KMT2A
SCHEMBL22063480 0.70 BACE1 (0.41) GABRB3GABRA2GABRB2HEXAHEXB
SCHEMBL22035472 0.68 NOTUM (0.38) GABRB3GABRA2GABRB2CYP1A2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240216516-A1 GLUTARIMIDE-CONTAINING KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF TIGER BIOTHERAPEUTICS INC. 2024-07-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240216516-A1 GLUTARIMIDE-CONTAINING KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF KRAS, VHL, HRAS GABRB3 1908/4885GABRA2 2016/4885GABRB2 1833/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.